dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Gürsoy, Pınar | |
dc.contributor.author | Çubukçu, Erdem | |
dc.contributor.author | Yıldız, Özcan | |
dc.contributor.author | Sakın, Abdullah | |
dc.contributor.author | Korkmaz, Taner | |
dc.contributor.author | Çil, İbrahim | |
dc.contributor.author | Çakar, Beyhan | |
dc.contributor.author | Menekşe, Serkan | |
dc.contributor.author | Demir, Tarık | |
dc.contributor.author | Açıkgöz, Özgen | |
dc.contributor.author | Hamdard, Jamshid | |
dc.date.accessioned | 2019-12-24T12:53:51Z | |
dc.date.available | 2019-12-24T12:53:51Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Bilici, A., Ölmez, Ö. F., Gürsoy, P., Çubukçu, E., Yıldız, Ö., Sakın, A. ... Hamdard, J. (2019). Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology içinde (S664-S665. ss.). https://doi.org/10.1016/j.jtho.2019.08.1407 | en_US |
dc.identifier.issn | 1556-1380 | |
dc.identifier.issn | 1556-0864 | |
dc.identifier.uri | https://doi.org/10.1016/j.jtho.2019.08.1407 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4653 | |
dc.description.abstract | The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been also investigated in patients with both early and advanced non-small-cell lung cancer (NSCLC). However, determination of SIR predicting outcomes of patients who are likely to response to crizotinib in ALK-positive NSCLC patients has not been clearly demonstrated. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Systemic Inflammatory | en_US |
dc.subject | ALK-Positive | en_US |
dc.subject | Cell | en_US |
dc.subject | Crizotinib | en_US |
dc.title | Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Journal of Thoracic Oncology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 14 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | S664 | en_US |
dc.identifier.endpage | S665 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.jtho.2019.08.1407 | en_US |
dc.identifier.wosquality | Q1 | en_US |